On March 27, 2024, Eli Lilly and Company announced that it has received a shareholder proposal from Trinity Health requesting Board to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents. Secondary and tertiary patents are patents applied for after the main active ingredient/molecule patent(s) and which relate to the product. The report on the process should be prepared at reasonable cost, omitting confidential and proprietary information, and be published on the Company?s website.

In addition, the board has recommended shareholders to vote against this proposal at the 2024 Annual Meeting to be held on May 6, 2024.